Emerald Mutual Fund Advisers Trust Sells 17,675 Shares of Alphatec Holdings, Inc. $ATEC

Emerald Mutual Fund Advisers Trust lessened its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 1.8% during the second quarter, HoldingsChannel.com reports. The fund owned 986,103 shares of the medical technology company’s stock after selling 17,675 shares during the period. Emerald Mutual Fund Advisers Trust’s holdings in Alphatec were worth $10,946,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Nuveen LLC bought a new stake in Alphatec during the 1st quarter worth approximately $135,874,000. Vanguard Group Inc. increased its holdings in Alphatec by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company’s stock worth $60,990,000 after acquiring an additional 45,792 shares during the period. American Century Companies Inc. increased its holdings in Alphatec by 16.9% during the 1st quarter. American Century Companies Inc. now owns 5,830,031 shares of the medical technology company’s stock worth $59,117,000 after acquiring an additional 840,974 shares during the period. Royal Bank of Canada increased its holdings in Alphatec by 10.8% during the 1st quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company’s stock worth $35,773,000 after acquiring an additional 342,656 shares during the period. Finally, Cerity Partners LLC increased its holdings in Alphatec by 1.6% during the 1st quarter. Cerity Partners LLC now owns 1,859,137 shares of the medical technology company’s stock worth $18,852,000 after acquiring an additional 30,072 shares during the period. Institutional investors own 66.35% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on ATEC. Stifel Nicolaus began coverage on shares of Alphatec in a report on Tuesday. They issued a “buy” rating and a $20.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Alphatec in a report on Tuesday, October 14th. Wells Fargo & Company increased their price target on shares of Alphatec from $14.00 to $16.00 and gave the stock an “overweight” rating in a report on Thursday, October 16th. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Friday, August 1st. Finally, Barclays reissued an “overweight” rating and issued a $22.00 price target (up previously from $21.00) on shares of Alphatec in a report on Monday, August 4th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.44.

Insider Buying and Selling

In related news, Director Mortimer Berkowitz III sold 62,500 shares of Alphatec stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $15.97, for a total value of $998,125.00. Following the transaction, the director owned 618,050 shares in the company, valued at $9,870,258.50. This trade represents a 9.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Scott Lish sold 36,081 shares of the firm’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $12.53, for a total transaction of $452,094.93. Following the completion of the sale, the chief operating officer directly owned 708,855 shares in the company, valued at approximately $8,881,953.15. This trade represents a 4.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 850,575 shares of company stock worth $12,902,127 over the last 90 days. Insiders own 20.90% of the company’s stock.

Alphatec Price Performance

Shares of NASDAQ:ATEC opened at $16.49 on Thursday. The stock has a market cap of $2.44 billion, a PE ratio of -14.59 and a beta of 1.05. The company’s fifty day moving average is $15.21 and its 200 day moving average is $13.16. Alphatec Holdings, Inc. has a 52 week low of $5.36 and a 52 week high of $17.15. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22.

Alphatec (NASDAQ:ATEC) last issued its earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.08. The business had revenue of $185.54 million during the quarter, compared to analysts’ expectations of $178.85 million. Alphatec’s revenue for the quarter was up 27.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.29) EPS. Research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.